Fiche du document
2020
- doi: 10.53738/revmed.2020.16.691.0831
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/revmed.2020.16.691.0831
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32348046
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_9CE1819469CE7
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Mots-clés
General MedicineSujets proches
TherapyCiter ce document
Alexandre Dumusc et al., « Rhumatologie et COVID-19 [Rheumatology and COVID-19] », Serveur académique Lausannois, ID : 10.53738/revmed.2020.16.691.0831
Métriques
Partage / Export
Résumé
Current pandemic implies changes in patient care in rheumatology to reduce the risk of coronavirus transmission to patients visiting health-care facilities, by organizing less frequent blood tests, using teleconsultations, and switching from intravenous to subcutaneous drug administration. Patients under immunosuppressive treatment are considered at high risk of severe outcome and are protected accordingly by the Swiss authorities. However, current, scarce scientific evidence suggests that patients under immunosuppressive therapy do not necessarily develop severe COVID-19 presentations. Therefore, the current guidelines recommend pursuing the treatment throughout the pandemic. In case of SARS-CoV-2 infection, immunosuppressive drugs should be temporarily stopped, except for glucocorticoids, hydroxychloroquine and sulfasalazine.